Evidence map›Paper›PMID 37695982›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer.

Pamela J Goodwin, Bingshu E Chen, Karen A Gelmon, Timothy J Whelan, Marguerite Ennis, Julie Lemieux, Jennifer A Ligibel, Dawn L Hershman, Ingrid A Mayer, Timothy J Hobday and 9 more

Open access · hybridAbstract readRandomized Controlled TrialClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 16 institutions in 4 countries.

Pamela J GoodwinLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, and Department of Medicine, University of Toronto, Toronto, ON, Canada.ORCID 0000-0003-2637-6906
Bingshu E ChenCanadian Cancer Trials Group, Queen's University, Kingston, ON, Canada.ORCID 0000-0001-6139-0696
Karen A GelmonUniversity of British Columbia, BC Cancer Agency, Vancouver, BC, Canada.ORCID 0000-0003-4111-2757
Timothy J WhelanMcMaster University, Juravinski Cancer Centre, Hamilton, ON, Canada.ORCID 0000-0001-9844-2023
Marguerite EnnisApplied Statistician, Markham, ON, Canada.ORCID 0000-0003-1094-5131
Julie LemieuxCHU de Québec-Université Laval, Québec, QC, Canada.
Jennifer A LigibelDana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-0633-3151
Dawn L HershmanHerbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY.ORCID 0000-0001-8807-153X
Ingrid A MayerVanderbilt University, Nashville, TN.ORCID 0000-0001-8147-335X
Timothy J HobdayMayo Clinic, Rochester, MN.ORCID 0000-0002-9877-3372
Judith M BlissICR-CTSU, Institute of Cancer Research (UK), London, United Kingdom.ORCID 0000-0001-7957-7424
Priya RastogiNRG Oncology and University of Pittsburgh Medical Center, Pittsburgh, PA.ORCID 0000-0002-6179-6407
Manuela Rabaglio-PorettiIBCSG and Department of Oncology, Bern University Hospital, University of Bern, Berne, Switzerland.
Alastair M ThompsonBaylor College of Medicine, Houston, TX.
Daniel W ReaCancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.ORCID 0000-0001-7301-4030
Paul M StosCanadian Cancer Trials Group, Queen's University, Kingston, ON, Canada.
Lois E ShepherdCanadian Cancer Trials Group, Queen's University, Kingston, ON, Canada.ORCID 0000-0002-5035-1621
Vuk StambolicPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Wendy R ParulekarCanadian Cancer Trials Group, Queen's University, Kingston, ON, Canada.ORCID 0000-0002-6007-7494
Queen's University · CABaylor College of Medicine · USBC Cancer Agency · CACancer Research UK Clinical Trials Unit · GBColumbia University Irving Medical Center · USDana-Farber Cancer Institute · USInstitute of Cancer Research · GBJuravinski Cancer Centre · CAMayo Clinic in Arizona · USMount Sinai Hospital · CAStatistics Canada · CAUniversité Laval · CAUniversity Health Network · CAUniversity of Bern · CHUniversity of Pittsburgh Medical Center · USVanderbilt University · US

Funding

NRG Oncology Network Group Operations CenterU10CA180868 · NRG ONCOLOGY FOUNDATION, INC. · 2025 to 2025
$15.3M
Statistics CoreU10CA180822 · UNIVERSITY OF CHICAGO · 2025 to 2025
$10.2M
NCIC Foreign AccrualsU10CA077202 · QUEEN'S UNIVERSITY AT KINGSTON · 1998 to 2005
$6.1M
Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials NetworkU10CA180863 · QUEEN'S UNIVERSITY AT KINGSTON · 2025 to 2025
$3.6M
Cancer Research UK 25354NCI NIH HHS U10 CA077202NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180863NCI NIH HHS U10 CA180868
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Breast NeoplasmsMetforminCanadaDouble-Blind MethodFemaleHumansMetformin

Identifiers

PMID37695982
PMCPMC10713140
OpenAlexW4386608505

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.